METASTATIC NON-SMALL CELL LUNG CANCER
Clinical trials for METASTATIC NON-SMALL CELL LUNG CANCER explained in plain language.
Never miss a new study
Get alerted when new METASTATIC NON-SMALL CELL LUNG CANCER trials appear
Sign up with your email to follow new studies for METASTATIC NON-SMALL CELL LUNG CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New combo drug shows promise in lung cancer battle
Disease control CompletedThis study tested a new drug that combines two immunotherapy agents (pembrolizumab and vibostolimab) with chemotherapy for people with advanced non-small cell lung cancer who haven't had treatment before. The goal was to see if this combination helps people live longer compared t…
Matched conditions: METASTATIC NON-SMALL CELL LUNG CANCER
Phase: PHASE3 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated May 16, 2026 22:48 UTC
-
New strategy zaps lung cancer spots before they grow
Disease control CompletedThis study tested whether giving focused treatments (like heat or freezing) to cancer spots in the body can help control advanced lung cancer that has spread. The approach uses a blood test to find tiny bits of cancer DNA (minimal residual disease) and treats when levels rise. 37…
Matched conditions: METASTATIC NON-SMALL CELL LUNG CANCER
Phase: PHASE2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated May 16, 2026 22:42 UTC
-
New drug combo shows promise for lung cancer brain metastases
Disease control CompletedThis study tested two drugs, amivantamab and lazertinib, in 43 adults with a specific type of lung cancer (EGFR-mutant) that had spread to the brain or spinal cord lining and was getting worse despite prior treatments. The goal was to see if the combination could shrink or contro…
Matched conditions: METASTATIC NON-SMALL CELL LUNG CANCER
Phase: PHASE2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated May 12, 2026 13:42 UTC
-
New drug combo shows promise for tough lung cancer
Disease control CompletedThis early-phase study tested the safety of combining two targeted drugs, dacomitinib and osimertinib, in 22 people with a specific type of advanced lung cancer (EGFR mutant). The goal was to find the highest safe dose and see if the combination could shrink tumors. Participants …
Matched conditions: METASTATIC NON-SMALL CELL LUNG CANCER
Phase: PHASE1 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated May 11, 2026 20:40 UTC
-
Muscle loss linked to immunotherapy response in lung cancer
Knowledge-focused CompletedThis study looked at 115 people with advanced lung cancer to see if muscle loss (sarcopenia) and a blood-based score called CTI could predict how well immunotherapy works. Researchers reviewed medical records and CT scans from patients treated at a single hospital. The goal is to…
Matched conditions: METASTATIC NON-SMALL CELL LUNG CANCER
Sponsor: Ankara Etlik City Hospital • Aim: Knowledge-focused
Last updated May 16, 2026 22:45 UTC
-
Blood test may reveal lung cancer treatment success early
Knowledge-focused CompletedThis study looked at 100 people with advanced lung cancer to see if changes in tumor DNA found in the blood could show whether their treatment was working. Researchers measured DNA levels before and after three weeks of therapy. The goal was to find an early sign of response or r…
Matched conditions: METASTATIC NON-SMALL CELL LUNG CANCER
Phase: NA • Sponsor: Centre Hospitalier Departemental Vendee • Aim: Knowledge-focused
Last updated May 13, 2026 15:58 UTC